Abstract

    Open Access Research Article Article ID: IJCEM-3-124

    Dipeptidyl Peptidase IV Inhibitory Activity of Berberine and Mangiferin: An In Silico Approach

    Ipseeta Ray Mohanty*, Selvaa Kumar and Rajesh Suman

    Background: Dipeptidyl peptidase-IV (DDP-IV) Inhibitors may represent single anti-diabetic drugs, the multiple actions of which may translate into demonstrable therapeutic benefits in   diabetes. The marketed synthetic DPP-IV Inhibitors are expensive drugs and have been reported to cause unacceptable adverse effects  such  as  pancreatitis,  angioedema,  thyroid  and  pancreatic  cancers.  In  this  scenario,  research  to  identify DPP-IV Inhibitors from alternative sources is desirable.

    Aims and Objective: The study was designed to elucidate the DPP-IV Inhibitory activity of Berberine and Mangiferin, determine the binding sites and affinity of Berberine and Mangiferin for DPP- IV enzyme using in silico studies and compare it to synthetic DPP-IV Inhibitor: Vildagliptin.

    Material  and  Methods: The  crystal  structure  of  human  DPP  IV  (PDB  Id:  2QT9)  was  downloaded  from Protein Databank. Berberine and Mangiferin were computationally designed and screened through in silico docking  studies  against  crystal  structure  of  DP-IV.  Computational  in  silico studies  were  used  to  identify  the  sites  as  well  as  amino  acid  residues  on  DPP-IV  enzyme  to  which  these  natural  DPP-IV  Inhibitors binds. 

    Results: The  DPP-IV  Inhibitory  activity  of  Mangiferin  was  found  to  be  comparable  to  synthetic  marketed DPP-IV Inhibitors; Vildagliptin and Sitagliptin. Like Vildagliptin, Berberine and Mangiferin bind within the active site pocket (the 1st largest pocket) of DPP-IV enzyme whereas, Sitagliptin prefers to bind in the second largest pocket of DPP-IV enzyme. Berberine prefers to bind to the active site pocket of DPP-IV enzyme. Berberine binds very close to Glu205 and Glu206. As delineated using in silico binding energy results, Mangiferin, possess superior DPP-IV inhibitory activity as compared to Sitagliptin and Vildagliptin.  

    Conclusion: In silico studies demonstrates that Berberine and Mangiferin possess significant DPP-IV Inhibitory activity comparable to marketed synthetic DPP-IV Inhibitors.

    Keywords: Berberine, Mangiferin; Sitagliptin; Vilda-gliptin; in silico and DPP-IV

    Published on: Jul 8, 2017 Pages: 18-22

    Full Text PDF Full Text HTML DOI: 10.17352/ijcem.000024
    CrossMark Publons Harvard Library HOLLIS Search IT Semantic Scholar Get Citation Base Search Scilit OAI-PMH ResearchGate Academic Microsoft GrowKudos Universite de Paris UW Libraries SJSU King Library SJSU King Library NUS Library McGill DET KGL BIBLiOTEK JCU Discovery Universidad De Lima WorldCat VU on WorldCat

    Indexing/Archiving

    Global Views

    Case Reports

    Peertechz Tweets

    Pinterest on IJCEM

    Google Reviews 11